Sensydia Raises $6 Million to Bring Non-Invasive Heart Monitoring to Clinics

The Cardiac Performance System, or CPS, functions by capturing acoustic and electrical signals, which are then processed through proprietary AI algorithms. By providing pulmonary pressure assessments without the physical risks of invasive catheterization, the technology aims to simplify how clinicians diagnose and treat patients suffering from heart failure and pulmonary hypertension. The system is designed to operate in office and clinic settings, shifting critical diagnostic capabilities away from hospital-only environments.

Industry momentum for this approach grew in July 2026 with the introduction of Category III CPT code 1036T, which covers non-invasive hemodynamic assessments using acoustic and electrical signals. Bill Hawkins, a former Medtronic CEO and current Sensydia advisor, noted that the company is effectively creating a new category of care by bringing pressure data directly to the point of decision. Victoria Grace of Colle Capital Partners cited the company's reliance on catheterization-based data as a clinical gold standard that differentiates its development process. As the company moves toward commercialization, CEO Anthony Arnold emphasized that the funding will accelerate their ability to provide objective pressure metrics to cardiologists precisely where therapy decisions are finalized.